Table 2 Risk analysis results of DMRs methylation levels of imprinted genes and CHD occurrence

GRB10

Q₁^c (< 39.67%)

6(26.1%)

1(4%)

1(reference)

Q₂–Q₃ ^d (39.67%–44%)

11(47.8%)

3(12%)

1.64(0.14–19.39)

Q₄^e (> 44%)

6(26.1%)

21(84%)

21.00(2.10–210.14)

MEST

Q₁ (< 49.36%)

5(22.7%)

1(5%)

1(reference)

Q₂–Q₃ (49.36%–56.07%)

12(54.5%)

9(45%)

3.75(0.371–37.95)

Q₄ (> 56.07%)

5(22.7%)

10(50%)

10.00(0.907–110.28)

PEG10

Q₁ (< 45.2%)

5(22.7%)

14(56%)

16.80(1.60–176.23)

Q₂–Q₃ (45.2%–55.7%)

11(50%)

10(40%)

5.46(0.56–53.52)

Q₄ (> 55.7%)

6(27.3%)

1(4%)

1(reference)

NAP1L5

Q₁ (< 67.14%)

6(26.1%)

9(45%)

3.50(0.64–19.20)

Q₂–Q₃ (67.14%–71.29%)

10(43.5%)

8(40%)

1.87(0.36–9.64)

Q₄ (> 71.29%)

7(30.4%)

3(15%)

1(reference)

INPP5F^f

Q₁ (< 70.39%)

4(23.5%)

17(77.3%)

11.06(2.47–49.53)

Q₂–Q4 (≥ 70.39%)

13(76.5%)

5(22.7%)

1(reference)

PLAGL1

Q₁ (< 40.76%)

6(24%)

11(42.3%)

11.00(1.06–114.09)

Q₂–Q₃ (40.76%–45.82%)

13(52%)

14(53.8%)

6.46(0.68–61.16)

Q₄ (> 45.82%)

6(24%)

1(3.8%)

1(reference)

MEG3^f

Q₁ (< 41.83%)

6(25%)

16(80%)

12.00(2.86–50.31)

Q₂–Q4 (≥ 41.83%)

18(75%)

4(20%)

1(reference)